Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.7040
+0.0147 (2.13%)
Aug 4, 2026, 3:16 PM EDT - Market open
Humacyte Revenue
Humacyte had revenue of $495.00K in the quarter ending March 31, 2026, a decrease of -4.26%. This brings the company's revenue in the last twelve months to $2.02M, up 289.94% year-over-year. In the year 2025, Humacyte had annual revenue of $2.04M.
Revenue (ttm)
$2.02M
Revenue Growth
+289.94%
P/S Ratio
92.19
Revenue / Employee
$10,957
Employees
184
Market Cap
189.83M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.57M | 302.00K | 23.91% |
| Dec 31, 2021 | 1.26M | -228.00K | -15.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 76.38M |
| Precision BioSciences | 45.07M |
| Voyager Therapeutics | 36.49M |
| MediWound | 14.48M |
| Pyxis Oncology | 13.86M |
| Alpha Cognition | 10.83M |
| Armata Pharmaceuticals | 5.20M |
| Outlook Therapeutics | 333.14K |
HUMA News
- 8 days ago - Humacyte announces FDA acceptance of CTEV IND application - TheFly
- 8 days ago - Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting - GlobeNewsWire
- 21 days ago - Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access - GlobeNewsWire
- 6 weeks ago - Humacyte price target lowered to $1.25 from $1.50 at TD Cowen - TheFly
- 7 weeks ago - Humacyte Slides: Corporate presentation - Filings
- 7 weeks ago - Humacyte Transcript: Study result - Transcripts
- 7 weeks ago - Humacyte Press release: Study result - Filings
- 7 weeks ago - Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting - GlobeNewsWire